Dali Pharmaceutical Co Ltd
Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection. The company's products include xingnaojing, shenmai, and astragalus injections, as well as citicoline injections. It also has patents, including invention patents and utility models. The company was founded in 1996 and is headquartered in Dali,… Read more
Dali Pharmaceutical Co Ltd (603963) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: -0.038x
Based on the latest financial reports, Dali Pharmaceutical Co Ltd (603963) has a cash flow conversion efficiency ratio of -0.038x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-14.75 Million) by net assets (CN¥390.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Dali Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2023)
This chart illustrates how Dali Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Dali Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dali Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arika Resources Ltd
AU:ARI
|
-0.024x |
|
Helios Energy Ltd
AU:HE8
|
-0.030x |
|
Kairous Acquisition Corp Ltd
NASDAQ:KACL
|
-0.008x |
|
RIV Capital Inc
PINK:CNPOF
|
0.048x |
|
Innosimulation Co., Ltd
KQ:274400
|
-0.020x |
|
Dunia Virtual Online Tbk Pt
JK:AREA
|
0.063x |
|
Agillic A/S
CO:AGILC
|
0.008x |
|
Santa Fe Minerals Ltd
AU:SFM
|
0.000x |
Annual Cash Flow Conversion Efficiency for Dali Pharmaceutical Co Ltd (2012–2023)
The table below shows the annual cash flow conversion efficiency of Dali Pharmaceutical Co Ltd from 2012 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | CN¥381.12 Million | CN¥-26.01 Million | -0.068x | -634.13% |
| 2022-12-31 | CN¥401.16 Million | CN¥-3.73 Million | -0.009x | -4.41% |
| 2021-12-31 | CN¥418.86 Million | CN¥-3.73 Million | -0.009x | +34.05% |
| 2020-12-31 | CN¥470.85 Million | CN¥-6.36 Million | -0.013x | -186.13% |
| 2019-12-31 | CN¥467.62 Million | CN¥7.33 Million | 0.016x | -90.69% |
| 2018-12-31 | CN¥464.13 Million | CN¥78.12 Million | 0.168x | +189.77% |
| 2017-12-31 | CN¥463.43 Million | CN¥26.92 Million | 0.058x | -86.12% |
| 2016-12-31 | CN¥211.98 Million | CN¥88.68 Million | 0.418x | -12.11% |
| 2015-12-31 | CN¥241.31 Million | CN¥114.86 Million | 0.476x | +34.34% |
| 2014-12-31 | CN¥270.52 Million | CN¥95.85 Million | 0.354x | -14.41% |
| 2013-12-31 | CN¥257.48 Million | CN¥106.59 Million | 0.414x | -32.01% |
| 2012-12-31 | CN¥165.45 Million | CN¥100.75 Million | 0.609x | -- |